⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884487 | 1.00 | — | — | |
| SCHEMBL3884492 | 1.00 | — | — | |
| SCHEMBL15320712 | 0.83 | FOLH1 (0.36) | — | |
| SCHEMBL15320713 | 0.83 | FOLH1 (0.36) | — | |
| SCHEMBL19501717 | 0.80 | — | — | |
| SCHEMBL27529709 | 0.79 | — | — | |
| SCHEMBL4410363 | 0.79 | — | — | |
| SCHEMBL5088899 | 0.77 | CA2 (0.41) | — | |
| SCHEMBL8751952 | 0.77 | — | — | |
| SCHEMBL3669379 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219325-B1 | VARIANTS OF THE LANTIBIOTIC MU1140 AND OTHER LANTIBIOTICS WITH IMPROVED PHARMACOLOGICAL PROPERTIES AND STRUCTURAL FEATURES | ORAGENICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9963488-B2 | Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features | ORAGENICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3219325-A1 | VARIANTS OF THE LANTIBIOTIC MU1140 AND OTHER LANTIBIOTICS WITH IMPROVED PHARMACOLOGICAL PROPERTIES AND STRUCTURAL FEATURES | Oragenics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9120861-B2 | Functional enhancement of antimicrobials | MISSISSIPPI STATE UNIVERSITY (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150125503-A1 | Variants of the Lantibiotic MU1140 and Other Lantibiotics with Improved Pharmacological Properties and Structural Features | ORAGENICS, INC. | 2015-05-07 | — | — | US | disclosed |
| EP-2833902-A1 | VARIANTS OF THE LANTIBIOTIC MU1140 AND OTHER LANTIBIOTICS WITH IMPROVED PHARMACOLOGICAL PROPERTIES AND STRUCTURAL FEATURES | Oragenics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013130349-A1 | VARIANTS OF THE LANTIBIOTIC MU1140 AND OTHER LANTIBIOTICS WITH IMPROVED PHARMACOLOGICAL PROPERTIES AND STRUCTURAL FEATURES | ORAGENICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2411404-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | Oragenics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1915389-B1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS INC (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010117652-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100145010-A1 | Functional enhancement of antimicrobials | MISSISSIPPI STATE UNIVERSITY | 2010-06-10 | — | — | US | disclosed |
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-7521529-B2 | Differentially protected orthogonal lanthionine technology | ORAGENICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1915389-A2 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | Oragenics, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007022012-A2 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037963-A1 | Lantibiotics; biosynthesis; solid phase synthesis; deblocking, deprotecting | ORAGENICS, INC. | 2007-02-15 | — | — | US | disclosed |